Proteostasis Therapeutics

Proteostasis Therapeutics concentrates on developing small-molecule drugs that modulate the proteostasis network — the cellular system governing protein folding, trafficking, and degradation. This approach targets diseases such as cystic fibrosis and neurodegenerative conditions where protein misfolding plays a central role. The company's pipeline has historically included CFTR modulators for cystic fibrosis.

Proteostasis Therapeutics is neither a family office nor a venture capital firm; it is a biotechnology company focused on drug discovery and development. It does not manage external capital or make investments in other companies. Its operations are centered on internal R&D programs rather than deploying capital as an allocator.

The firm is headquartered in Cambridge, Massachusetts, United States, a key cluster for life sciences and biotech innovation. No additional offices have been publicly identified.

Specific founder names have not been widely disclosed in public sources. The company was established by experts in protein homeostasis and cellular stress biology, but the founding team's identities are not part of the public record.

Proteostasis Therapeutics does not publicly disclose its AUM, deployment, or financial backing. No fundraising rounds, revenue figures, or valuation data are available in public records. The firm's ownership structure and financial support remain undisclosed.